NCT06864572

[68Ga]Ga-P17-079 in the Diagnosis and Treatment of Metastatic Prostate Cancer

Clinical Application of Dual-target Imaging Agent [68Ga]Ga-P17-079 in the Diagnosis and Treatment of Metastatic Prostate Cancer

• Status: Enrolling By Invitation
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Peking Union Medical College Hospital · Academic / Other
• Sex: Male
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

Preclinical studies have confirmed that \[68Ga\]Ga-P17-079 in both mouse prostate tumors and osseogenic metastases has high uptake and prolonged retention, which enables \[68Ga\]Ga-P17-079 to be fully absorbed by the lesions, and it is possible to detect bone metastases, prostate cancer primary sites, lymph node metastases and organ metastases at the same time in a single examination. It is a potential "killing two birds with one stone" imaging agent. At this stage, the clinical study of \[68Ga\]Ga-P17-079 in the diagnosis and treatment of metastatic prostate cancer as a self-made preparation is planned to be carried out in our hospital to further verify its clinical application value.

Conditions

• Metastatic Prostate Cancer (mPC)

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	P17-079, P16-093, or P15-041 PET/CT	P17-079, P16-093, or P15-041 PET/CT

Timeline

• Start date: 2024-09-01
• Primary completion: 2026-09-01
• Completion: 2027-09-01
• First posted: 2025-03-07
• Last updated: 2025-03-07

Locations

1 site across 1 country: China